 | ||||||||||||||||||||||||||||||||||||
 |
PASSION FOR IDEAS |
|||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||
|
|
Endotis PharmaEndotis Pharma is a biotech-pharma company created in 2003 and specializes in the discovery and development of small glycan drugs (SGDs). Their properties (solubility, stability, metabolism…) provide SGDs a number of key advantages over other therapeutics, yet, probably due to the difficulty of their chemistry, it is only recently that the pharmaceutical industry has begun to exploit this great potential; the anti-thrombotics Fondaparinux and Idraparinux, for instance, are derived from heparin. Through internal research and in-licensing, Endotis has developed a solid, innovative and very promising thrombosis pipeline, with a first candidate entering phase II (indication: acute coronary syndrom) and two others entering Phase I.
May 19, 2009 Endotis Pharma reports successful completion of phase I program with EP42675, a first in class synthetic parenteral anticoagulant January 23, 2008 Endotis Pharma Raises €25 million in a Second Financing Round |
|
|
|
|||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||
| partner of the European Tech Tour |  |
"With Endeavour Vision you benefit first and foremost from smart investor feed back challenging your plans that helps you to move a step further, but at the same time you get practical and worthwhile input from professionals who know the business from the inside" Charles Woler, CEO, Endotis |
||||||||||||||||||||||||||||||||||
investments
technology
Olivier Valdenaire
Sven Lingjaerde